Related Experiment Video
Updated: Mar 10, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Does the addition of ezetimibe to statins reduce cardiovascular risk?
Francisca I Araya1, Bruno Grassi2
1Proyecto Epistemonikos, Santiago, Chile. Address: Facultad de Medicina, Pontificia Universidad Católica de Chile, Diagonal Paraguay 476, Santiago Centro, Chile.
Insights
Adding ezetimibe to statins likely offers minimal impact on overall mortality for patients. This combination may slightly decrease risks of heart attack and stroke, though evidence certainty is low.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Statins are primary lipid-lowering agents for cardiovascular risk reduction.
- Many patients do not achieve guideline-recommended lipid goals with statins alone.
- Residual cardiovascular risk persists even in patients at goal.
Purpose of the Study:
- To evaluate the efficacy and safety of adding ezetimibe to statin therapy.
- To synthesize current evidence on ezetimibe-statin combination therapy.
Main Methods:
- Systematic review and meta-analysis of 67 trials.
- Evidence synthesized using the GRADE approach for certainty assessment.
Main Results:
- Adding ezetimibe to statins showed little to no difference in overall mortality.
- A potential small reduction in myocardial infarction and stroke risk was observed.
- The certainty of evidence for these outcomes was rated as low.
Conclusions:
- Ezetimibe addition to statins may offer a slight benefit in reducing cardiovascular events.
- Further high-certainty evidence is needed to confirm the benefits of ezetimibe-statin therapy.
Abstract:
Statins are the mainstay of lipid-lowering therapy nowadays, since they reduce cardiovascular risk when used as primary or secondary prevention. However, only one third of the patients reach the goals established in several guidelines, and even if they do, they keep a risk higher than healthy controls. One of the new lipid-lowering agents is ezetimibe. Searching in Epistemonikos database, which is maintained by screening multiple databases, we identified nine systematic reviews comprising 67 trials overall. We combined the evidence using meta-analysis and generated a summary of findings following the GRADE approach. We concluded adding ezetimibe to statins probably results in little or no difference in overall mortality. It might lead to a small reduction in the risk of myocardial infarction and stroke, but the certainty of the evidence is low.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Coronary Artery Disease IV: Preventive Measures
Cholesterol: Significance and Regulation
Considering cholesterol and...
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Lipids: Dietary Sources and Requirements
